JP2003530070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003530070A5 JP2003530070A5 JP2000618329A JP2000618329A JP2003530070A5 JP 2003530070 A5 JP2003530070 A5 JP 2003530070A5 JP 2000618329 A JP2000618329 A JP 2000618329A JP 2000618329 A JP2000618329 A JP 2000618329A JP 2003530070 A5 JP2003530070 A5 JP 2003530070A5
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- region
- fusion protein
- nucleic acid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108060003951 Immunoglobulin Proteins 0.000 description 21
- 102000018358 immunoglobulin Human genes 0.000 description 21
- 102000037865 fusion proteins Human genes 0.000 description 15
- 108020001507 fusion proteins Proteins 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000006992 Interferon-alpha Human genes 0.000 description 4
- 108010047761 Interferon-alpha Proteins 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13489599P | 1999-05-19 | 1999-05-19 | |
| US60/134,895 | 1999-05-19 | ||
| PCT/US2000/013827 WO2000069913A1 (en) | 1999-05-19 | 2000-05-19 | EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003530070A JP2003530070A (ja) | 2003-10-14 |
| JP2003530070A5 true JP2003530070A5 (enExample) | 2007-07-05 |
Family
ID=22465500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000618329A Pending JP2003530070A (ja) | 1999-05-19 | 2000-05-19 | Ｆｃ融合タンパク質としてのインターフェロン−αタンパク質の発現および搬出 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20020081664A1 (enExample) |
| EP (1) | EP1187852B1 (enExample) |
| JP (1) | JP2003530070A (enExample) |
| KR (1) | KR20020018197A (enExample) |
| CN (1) | CN1361793A (enExample) |
| AT (1) | ATE369384T1 (enExample) |
| AU (1) | AU777963B2 (enExample) |
| BR (1) | BR0010725A (enExample) |
| CA (1) | CA2372400C (enExample) |
| CZ (1) | CZ20014123A3 (enExample) |
| DE (1) | DE60035871T2 (enExample) |
| DK (1) | DK1187852T3 (enExample) |
| ES (1) | ES2291205T3 (enExample) |
| HK (1) | HK1046694A1 (enExample) |
| HU (1) | HUP0201474A3 (enExample) |
| MX (1) | MXPA01011845A (enExample) |
| NO (1) | NO20015587L (enExample) |
| PL (1) | PL352332A1 (enExample) |
| PT (1) | PT1187852E (enExample) |
| RU (1) | RU2262510C9 (enExample) |
| WO (1) | WO2000069913A1 (enExample) |
| ZA (1) | ZA200109227B (enExample) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| ES2590912T3 (es) | 1997-12-08 | 2016-11-24 | Merck Patent Gmbh | Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario |
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| HK1038882A1 (zh) * | 1998-04-15 | 2002-04-04 | 利思进药品公司 | 通过共同给予血管生成抑制剂增强抗体-细胞因子融合蛋白介导的免疫应答 |
| ATE369384T1 (de) * | 1999-05-19 | 2007-08-15 | Emd Lexigen Res Ct Corp | Expression und export von interferon-alpha proteinen als fc fusionsproteine |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| AU778611B2 (en) | 1999-08-09 | 2004-12-16 | Merck Patent Gmbh | Multiple cytokine-antibody complexes |
| US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| ATE336514T1 (de) | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
| CA2405550A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| ATE368475T1 (de) | 2000-06-29 | 2007-08-15 | Emd Lexigen Res Ct Corp | Steigerung von durch antikörper-zytokin- fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| BR0207854A (pt) * | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido |
| WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| US20030065148A1 (en) * | 2001-05-02 | 2003-04-03 | Villarete Lorelie H. | Method for expression of human interferon alpha 1 in Pichia pastoris |
| DK1383785T3 (da) | 2001-05-03 | 2011-05-23 | Merck Patent Gmbh | Rekombinant tumorspecifikt antistof og anvendelse deraf |
| PT1454138E (pt) | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| AU2002364586A1 (en) | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| WO2004046365A2 (en) * | 2002-11-18 | 2004-06-03 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| US7314613B2 (en) | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| DK1572748T3 (da) * | 2002-12-17 | 2010-08-23 | Merck Patent Gmbh | Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2 |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| MXPA05008704A (es) * | 2003-02-18 | 2005-10-05 | Merck Patent Gmbh | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. |
| US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| US20040180054A1 (en) * | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| DE602004031390D1 (de) * | 2003-05-06 | 2011-03-24 | Syntonix Pharmaceuticals Inc | Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten |
| CA2522690A1 (en) * | 2003-05-06 | 2004-11-25 | Syntonix Pharmaceuticals, Inc. | Inhibition of drug binding to serum albumin |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| US8383132B2 (en) * | 2003-10-16 | 2013-02-26 | The Regents Of The University Of California | Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use |
| CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| BRPI0406606A (pt) | 2003-11-13 | 2005-12-06 | Hanmi Pharm Ind Co Ltd | Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo |
| US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
| ES2305886T3 (es) | 2003-12-30 | 2008-11-01 | Merck Patent Gmbh | Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo. |
| KR20060124656A (ko) | 2003-12-31 | 2006-12-05 | 메르크 파텐트 게엠베하 | 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질 |
| US8420087B2 (en) | 2004-01-05 | 2013-04-16 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
| EP1706428B1 (en) * | 2004-01-22 | 2009-09-23 | MERCK PATENT GmbH | Anti-cancer antibodies with reduced complement fixation |
| AU2008201682B2 (en) * | 2004-02-02 | 2011-02-24 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
| BRPI0507159A (pt) | 2004-02-02 | 2007-06-26 | Ambrx Inc | polipeptìdeos em feixe de quatro hélices humanos modificados e seus usos |
| US7318918B2 (en) | 2004-05-19 | 2008-01-15 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| DK2412728T3 (en) | 2004-08-03 | 2015-04-07 | Innate Pharma | Therapeutic compositions for cancer, that target 4Ig-B7-H3 |
| JP4937132B2 (ja) | 2004-12-09 | 2012-05-23 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 免疫原性の低下したｉｌ−７変種 |
| EP2311880A3 (en) | 2005-01-05 | 2011-07-27 | Biogen Idec MA Inc. | Cripto binding molecules |
| US20170121692A1 (en) * | 2005-04-06 | 2017-05-04 | Ibc Pharmaceuticals, Inc. | Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses |
| US8158129B2 (en) * | 2005-04-06 | 2012-04-17 | Ibc Pharmaceuticals, Inc. | Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo |
| AU2006299901A1 (en) | 2005-05-18 | 2007-04-19 | Maxygen, Inc. | Evolved interferon-alpha polypeptides |
| US7566456B2 (en) * | 2005-06-23 | 2009-07-28 | Haiming Chen | Allergen vaccine proteins for the treatment and prevention of allergic diseases |
| HUE026303T2 (hu) | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával |
| WO2007021129A1 (en) | 2005-08-16 | 2007-02-22 | Hanmi Pharmaceutical Co., Ltd. | A method for the mass production of immunoglobulin fc region deleted initial methionine residues |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| ES2365046T3 (es) | 2005-12-30 | 2011-09-21 | Merck Patent Gmbh | Anticuerpos anti-cd19 con inmunogenicidad reducida. |
| PT1966238E (pt) * | 2005-12-30 | 2012-07-31 | Merck Patent Gmbh | Uso de hsp70 como um regulador de atividade enzimática |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| US8454948B2 (en) | 2006-09-14 | 2013-06-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
| KR101470472B1 (ko) | 2006-09-14 | 2014-12-09 | 메드제닉스 메디칼 이스라엘 리미티드 | 장기 지속형 약물 제형 |
| US9127084B2 (en) | 2006-09-14 | 2015-09-08 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
| CN1944463B (zh) * | 2006-10-30 | 2010-05-12 | 中国科学技术大学 | 具有α干扰素活性的融合蛋白及其编码基因与应用 |
| AU2009234277B2 (en) | 2008-04-11 | 2014-12-04 | Aptevo Research And Development Llc | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| MX2011011044A (es) | 2009-04-22 | 2011-11-04 | Merck Patent Gmbh | Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados. |
| WO2011064758A2 (en) * | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
| EP3403647A1 (en) | 2009-12-01 | 2018-11-21 | Translate Bio, Inc. | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| CN102585013B (zh) * | 2011-01-07 | 2014-04-23 | 中国人民解放军军事医学科学院生物工程研究所 | 一种含有ω干扰素的融合蛋白及制备方法 |
| WO2012170072A1 (en) * | 2011-06-06 | 2012-12-13 | Immungene, Inc. | Engineered antibody-tnfsf member ligand fusion molecules |
| US20140206753A1 (en) | 2011-06-08 | 2014-07-24 | Shire Human Genetic Therapies, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
| EP2859102A4 (en) | 2012-06-08 | 2016-05-11 | Shire Human Genetic Therapies | NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF |
| US8784834B2 (en) | 2012-07-24 | 2014-07-22 | Sbc Virbac Biotech Co., Ltd. | Recombinant fusion interferon for animals |
| US8956623B2 (en) | 2012-07-24 | 2015-02-17 | Sbc Virbac Limited | Recombinant fusion interferon for animals |
| ES2981185T3 (es) | 2013-03-14 | 2024-10-07 | Translate Bio Inc | Métodos para la purificación de ARN mensajero |
| EP3431592A1 (en) * | 2013-03-14 | 2019-01-23 | Translate Bio, Inc. | Mrna therapeutic compositions and use to treat diseases and disorders |
| CA2904151C (en) | 2013-03-14 | 2023-09-12 | Shire Human Genetic Therapies, Inc. | Cftr mrna compositions and related methods and uses |
| LT6164B (lt) | 2013-10-15 | 2015-06-25 | Uab Biotechnologinės Farmacijos Centras "Biotechpharma" | Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas |
| WO2015061491A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
| BR112016009014B1 (pt) | 2013-10-22 | 2024-02-06 | Translate Bio, Inc | USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE |
| MX373952B (es) | 2014-04-25 | 2020-07-13 | Shire Human Genetic Therapies | Métodos de purificación de arn mensajero. |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| US11661455B2 (en) * | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| MX2019010155A (es) | 2017-02-27 | 2020-12-10 | Translate Bio Inc | Arnm de cftr optimizado por codón novedoso. |
| AU2018246292A1 (en) | 2017-03-31 | 2019-10-10 | Accanis Biotech F&E Gmbh & Co Kg | Prevention and treatment of non-melanoma skin cancer (NMSC) |
| MA49138A (fr) | 2017-05-16 | 2020-03-25 | Translate Bio Inc | Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr |
| RU2650755C1 (ru) * | 2017-05-24 | 2018-04-17 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С |
| CN107254482A (zh) * | 2017-07-18 | 2017-10-17 | 哈尔滨紫霞生物科技有限公司 | 一种提高重组猪干扰素‑α融合蛋白抗病毒活性的方法 |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| CU24554B1 (es) * | 2018-05-07 | 2021-11-04 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 |
| WO2020041793A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| AU2019384557B2 (en) | 2018-11-21 | 2025-07-17 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR |
| CA3136602A1 (en) | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
| AU2020398327A1 (en) | 2019-12-03 | 2022-07-14 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| AU2021301953B2 (en) * | 2020-07-01 | 2025-01-02 | Institute Of Biophysics, Chinese Academy Of Sciences | Construction and application of fusion protein vaccine platform |
| RU2764787C1 (ru) * | 2020-12-08 | 2022-01-21 | Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) | Рекомбинантная плазмидная ДНК, кодирующая химерный интерферон alpha2b, рекомбинантный штамм дрожжей P. pastoris X33 - продуцент химерного интерферона alpha2b и способ получения указанного белка |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4469797A (en) * | 1982-09-23 | 1984-09-04 | Miles Laboratories, Inc. | Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives |
| SU1092176A1 (ru) * | 1982-09-24 | 1984-05-15 | Институт биоорганической химии им.М.М.Шемякина | Способ получени искусственного гена интерферона @ 2 человека и способ получени полипептида с активностью интерферона микробиологическим синтезом |
| US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| US5082658A (en) * | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
| US5679543A (en) * | 1985-08-29 | 1997-10-21 | Genencor International, Inc. | DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi |
| US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5359035A (en) * | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
| US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| AU600575B2 (en) * | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4732462A (en) * | 1987-04-27 | 1988-03-22 | Ronald Bel | Safety viewing apparatus for crane car |
| US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5120525A (en) * | 1988-03-29 | 1992-06-09 | Immunomedics, Inc. | Radiolabeled antibody cytotoxic therapy of cancer |
| US5601819A (en) * | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US6750329B1 (en) * | 1989-05-05 | 2004-06-15 | Research Development Foundation | Antibody delivery system for biological response modifiers |
| US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| ATE123065T1 (de) * | 1989-07-07 | 1995-06-15 | Takeda Chemical Industries Ltd | Proteine und deren herstellung. |
| SK280670B6 (sk) * | 1989-09-27 | 2000-05-16 | Gist-Brocades N.V. | Vyčistená a izolovaná sekvencia dna, konštrukt, ve |
| US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| US7253264B1 (en) * | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| US5709859A (en) * | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
| US20020037558A1 (en) * | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
| US6627615B1 (en) * | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
| WO1993024135A1 (en) * | 1992-05-26 | 1993-12-09 | Immunex Corporation | Novel cytokine that binds cd30 |
| AU4528493A (en) * | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
| US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
| CA2142007C (en) * | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
| DE4228839A1 (de) * | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Verfahren zum Nachweis und zur Bestimmung von Mediatoren |
| US5554512A (en) * | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6485726B1 (en) * | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| JP3342873B2 (ja) * | 1995-03-10 | 2002-11-11 | ジェネンテク・インコーポレイテッド | ｇａｓ６による受容体活性化 |
| US6281010B1 (en) * | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| US6620413B1 (en) * | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| ES2176574T3 (es) * | 1996-09-03 | 2002-12-01 | Gsf Forschungszentrum Umwelt | Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral. |
| US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
| US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| ES2590912T3 (es) * | 1997-12-08 | 2016-11-24 | Merck Patent Gmbh | Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario |
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| US6284536B1 (en) * | 1998-04-20 | 2001-09-04 | The Regents Of The University Of California | Modified immunoglobin molecules and methods for use thereof |
| CA2341029A1 (en) * | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6646113B1 (en) * | 1998-09-17 | 2003-11-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants |
| US6335176B1 (en) * | 1998-10-16 | 2002-01-01 | Pharmacopeia, Inc. | Incorporation of phosphorylation sites |
| ATE418340T1 (de) * | 1999-05-06 | 2009-01-15 | Univ Wake Forest | Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen |
| ATE369384T1 (de) * | 1999-05-19 | 2007-08-15 | Emd Lexigen Res Ct Corp | Expression und export von interferon-alpha proteinen als fc fusionsproteine |
| AU778611B2 (en) * | 1999-08-09 | 2004-12-16 | Merck Patent Gmbh | Multiple cytokine-antibody complexes |
| ATE336514T1 (de) * | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
| NZ522320A (en) * | 2000-05-12 | 2007-03-30 | Neose Technologies Inc | In vitro modification of glycosylation patterns of recombinant glycopeptides |
| ATE368475T1 (de) * | 2000-06-29 | 2007-08-15 | Emd Lexigen Res Ct Corp | Steigerung von durch antikörper-zytokin- fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme |
| BR0207854A (pt) * | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido |
| DK1383785T3 (da) * | 2001-05-03 | 2011-05-23 | Merck Patent Gmbh | Rekombinant tumorspecifikt antistof og anvendelse deraf |
-
2000
- 2000-05-19 AT AT00932622T patent/ATE369384T1/de active
- 2000-05-19 ES ES00932622T patent/ES2291205T3/es not_active Expired - Lifetime
- 2000-05-19 MX MXPA01011845A patent/MXPA01011845A/es unknown
- 2000-05-19 EP EP00932622A patent/EP1187852B1/en not_active Expired - Lifetime
- 2000-05-19 BR BR0010725-5A patent/BR0010725A/pt not_active IP Right Cessation
- 2000-05-19 HU HU0201474A patent/HUP0201474A3/hu unknown
- 2000-05-19 WO PCT/US2000/013827 patent/WO2000069913A1/en not_active Ceased
- 2000-05-19 HK HK02108255.1A patent/HK1046694A1/zh unknown
- 2000-05-19 JP JP2000618329A patent/JP2003530070A/ja active Pending
- 2000-05-19 DE DE60035871T patent/DE60035871T2/de not_active Expired - Lifetime
- 2000-05-19 CZ CZ20014123A patent/CZ20014123A3/cs unknown
- 2000-05-19 PL PL00352332A patent/PL352332A1/xx unknown
- 2000-05-19 KR KR1020017014691A patent/KR20020018197A/ko not_active Ceased
- 2000-05-19 RU RU2001130984/13A patent/RU2262510C9/ru not_active IP Right Cessation
- 2000-05-19 AU AU50318/00A patent/AU777963B2/en not_active Expired
- 2000-05-19 PT PT00932622T patent/PT1187852E/pt unknown
- 2000-05-19 CA CA2372400A patent/CA2372400C/en not_active Expired - Lifetime
- 2000-05-19 DK DK00932622T patent/DK1187852T3/da active
- 2000-05-19 CN CN00810671A patent/CN1361793A/zh active Pending
-
2001
- 2001-10-11 US US09/977,034 patent/US20020081664A1/en not_active Abandoned
- 2001-11-08 ZA ZA200109227A patent/ZA200109227B/en unknown
- 2001-11-15 NO NO20015587A patent/NO20015587L/no not_active Application Discontinuation
-
2004
- 2004-09-29 US US10/953,259 patent/US20050042729A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003530070A5 (enExample) | ||
| RU2001130984A (ru) | Экспрессия и экспорт белков интерферона-альфа в виде слитых белков, содержащих Fc-фрагмент иммуноглобулина | |
| CA2372400A1 (en) | Expression and export of interferon-alpha proteins as fc fusion proteins | |
| JP2002523036A5 (enExample) | ||
| JPH07501698A (ja) | 二価特異性ヘテロ二量体 | |
| JP2003507012A5 (enExample) | ||
| ATE169959T1 (de) | Anthrax-toxin-fusionsproteine und deren verwendungen | |
| NO20024475D0 (no) | Produksjon av rekombinante blodkoagulasjonsfaktorer i humane cellelinjer | |
| JP2001514858A5 (enExample) | ||
| ATE342359T1 (de) | Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften | |
| DE69835085D1 (de) | Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor | |
| JPS63503275A (ja) | ファクター８：ｃの製造方法 | |
| ATE363533T1 (de) | Osteoprotegerin bindende proteine und rezeptoren | |
| JP2014519830A5 (enExample) | ||
| PT721505E (pt) | Proteinas do envelope do virus da hepatite c purificadas para utilizacao em diagnostico e terapeutica | |
| WO1991019515A1 (en) | Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity | |
| JP3805358B2 (ja) | フォン・ウィルブランド因子の治療用ドメイン | |
| AU622891B2 (en) | Cleaved dimers of mullerian inhibiting substance-like polypeptides | |
| CA2311648A1 (en) | Ifnar2/ifn complex | |
| MXPA04005891A (es) | Proteinas envolventes del virus de hepatitis c purificadas para diagnostico y uso terapeutico. | |
| Zhu et al. | Inter-chain disulfide bond improved protein trans-splicing increases plasma coagulation activity in C57BL/6 mice following portal vein FVIII gene delivery by dual vectors | |
| RU2336279C2 (ru) | БЕЛОК IFNAB-BPI, ЕГО ПРЕДШЕСТВЕННИК, МОЛЕКУЛА ДНК, ЭКСПРЕССИРУЮЩИЙ ВЕКТОР, СПОСОБ ПРОДУЦИРОВАНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ IFN-α ИЛИ IFN-β | |
| Black | Drug products of recombinant DNA technology | |
| JP3047020B1 (ja) | 固定化蛋白質の製造法 | |
| KR100686356B1 (ko) | 중공 나노입자를 형성하는 단백질에 질환 치료용 세포도입 물질을 융합시킨 약제 |